Azenta, Inc. · NASDAQ:AZTA

Azenta — Baird 2023 Global Healthcare Conference

32 slides from Azenta's conference presentation, Sep 12, 2023

  1. Slide 1: Baird 2023 Global Healthcare Conference

    Slide 1: Baird 2023 Global Healthcare Conference

    Azenta Life Sciences Baird 2023 Global Healthcare Conference September 12, 2023

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co

  3. Slide 3: Agenda

    Slide 3: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Developing and Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profit

  4. Slide 4: Azenta is Enabling Life Sciences Organizations to Bring Breakthrough Therapies to Market Faster

    Slide 4: Azenta is Enabling Life Sciences Organizations to Bring Breakthrough Therapies to Market Faster

    Azenta is Enabling Life Sciences Organizations to Bring Breakthrough Therapies to Market – Faster >9,000 >180 ~3,500 ~$1.0B Customers Countries Served Employees Available Cash1 Market Leading Offerings: Growth Rate (YtY)2 Products Services Q3’23 YTD Q3’23 • Genomics services • Biorepository and samp

  5. Slide 5: Established Early, Recognized as a Leader in Life Sciences

    Slide 5: Established Early, Recognized as a Leader in Life Sciences

    Established Early, Recognized as a Leader in Life Sciences To >$500M by FY’22 ~$657M • Genomic services and analytics • Additional sample repository and consumables & instruments (C&I) $555M capabilities • Sample sourcing • Informatics To $100M in First 5 Years • Automated ultracold stores • Consuma

  6. Slide 6: Track Record of Value Creation and Positioned to Increase Growth and Profitability

    Slide 6: Track Record of Value Creation and Positioned to Increase Growth and Profitability

    Track Record of Value Creation and Positioned to Increase Growth and Profitability Progress to Date Well Positioned for the Future Life sciences leader with >$600M of Cost reductions taken to enhance revenue growth since 2011 operating leverage for margin expansion Portfolio addressing end-markets w

  7. Slide 7: Agenda

    Slide 7: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Developing and Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profit

  8. Slide 8: Strategically Positioned to Address Market Needs

    Slide 8: Strategically Positioned to Address Market Needs

    Strategically Positioned to Address Market Needs 2X >30% >2,000 Growth in outsourced 2021 FDA drug approvals Cell & Gene Therapy active samples in 5 years require temperature control trials today1 • Increased requirements for • Regulations necessitate • CGT market poised for better sample management

  9. Slide 9: An Impressive Roster of Customers Use Azenta's Solutions

    Slide 9: An Impressive Roster of Customers Use Azenta's Solutions

    An Impressive Roster of Customers Use Azenta’s Solutions 9,000+ 24,000 Top 5 33 Citations in Total customers served by Azenta Best-selling pharma 20 of 20 scientific journals products: clinical samples managed by SRS Nobel laureate Top pharma/biotech labs use Azenta served by Azenta Pharma / Biotech

  10. Slide 10: Building on a 15+ Year Global Large Pharma Relationship

    Slide 10: Building on a 15+ Year Global Large Pharma Relationship

    CUSTOMER CASE STUDY Building on a 15+ Year Global Large Pharma Relationship: Enabling a Best-in-Class R&D Program 2000s-2019 2020 2021 2022 2023 Early adopter of Expanded Added 3 large automated GENEWIZ automated Added Sample Reached >5M stores and services stores Repository samples stored GENEWIZ P

  11. Slide 11: Azenta Portfolio – Diverse and Differentiated

    Slide 11: Azenta Portfolio – Diverse and Differentiated

    Azenta Portfolio – Diverse and Differentiated Next Generation Sequencing B Medical 16% Sanger Systems Sequencing 17% 9% Gene Synthesis Products & Other Services 13% 45% Ultracold Systems 55% & Services 16% Sample Repository Consumables Solutions & Instruments 17% 12% Note: FY’23 Year-to-Date (9 mont

  12. Slide 12: B Medical, a Global Leader in Temperature-Controlled Storage and Transportation Solutions

    Slide 12: B Medical, a Global Leader in Temperature-Controlled Storage and Transportation Solutions

    B Medical, a Global Leader in Temperature-Controlled Storage and Transportation Solutions B Medical Today Future Opportunities FY’23E $108M Revenue1 ➢ Distinct and Attractive Business • A global leader in vaccine cold chain Cold chain • Unique position to serve fast-growing 500k+ units shipped emerg

  13. Slide 13: Agenda

    Slide 13: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Developing and Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profit

  14. Slide 14: Long Track Record of Growth Supported with Organic and M&A Investment

    Slide 14: Long Track Record of Growth Supported with Organic and M&A Investment

    Long Track Record of Growth Supported with Organic and M&A Investment Revenue $700 Acquisitions COVID $600 Organic 33% CAGR $500 $ millions $400 $300 $200 $100 $- FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23E Note: FY23E based on the midpoint of FY’23 guidance as of August 8, 2023, and is being prov

  15. Slide 15: Business Realignment Enhances Commercial Strategy and Supports Growth

    Slide 15: Business Realignment Enhances Commercial Strategy and Supports Growth

    Business Realignment Enhances Commercial Strategy and Supports Growth Sample 1 Management Solutions Operating 2 Multiomics Units 3 B Medical Three operational groups aligned with industry end-users and purchase decision-makers Note: Effective 10/1/23, at the start of FY24 15 © 2023 Azenta, Inc. • Pr

  16. Slide 16: Margin Improvement Actions In Process

    Slide 16: Margin Improvement Actions In Process

    Margin Improvement Actions In Process Integration and Realignment of Internal Rationalization of Operations Acquired Businesses • $14M annual net cost savings • $15M annual cost savings by • Expected to drive 2 points of the end of CY2023 to support +4pts EBITDA margin enhancement in the second half

  17. Slide 17: Continued Disciplined Approach to Capital Deployment

    Slide 17: Continued Disciplined Approach to Capital Deployment

    Continued Disciplined Approach to Capital Deployment Operational CapEx ~6-9% of Revenue Research & ~4-6% of Revenue Development Shareholder Returning Capital Through $1B Value Share Repurchases by CY23 End Strong Balance ~$1B Cash Available for Deployment* Sheet *Estimated based on $1.3B in cash as

  18. Slide 18: Guidance As Provided August 8, 2023

    Slide 18: Guidance As Provided August 8, 2023

    Guidance As Provided August 8, 2023 Continuing Operations August Q3’22 Q4’22 Q1’23 Q2’23 Q3’23 Guidance Q4’23 * Total Revenue ($M) $133 $138 $178 $148 $166 $155 - $173 Organic Growth %* 6% 2% (1%) (8%) 2% ~(1)% Organic Growth ex-C&I %* 11% 9% 4% 1% 8% ~3% Adjusted EBITDA ($M)* $14 $9 $12 ($2) $13 $2

  19. Slide 19: Differentiated End-to-End Sample Management Portfolio

    Slide 19: Differentiated End-to-End Sample Management Portfolio

    Differentiated End-to-End Sample Management Portfolio ~$660M run-rate revenue, well-positioned for 1 growth and margin expansion in robust end markets Strong value proposition with Global platform that can support additional 2 capabilities and customers unique portfolio of sample-based solutions Hea

  20. Slide 20: Appendix

    Slide 20: Appendix

    / \ AZENTA LIFE SCIENCES Appendix

  21. Slide 21: 10+ Years Building a Leading-Edge Life Sciences Company

    Slide 21: 10+ Years Building a Leading-Edge Life Sciences Company

    10+ Years Building a Leading-Edge Life Sciences Company 2011-2012 2013-2014 2015-2016 2017-2018 2019-2020 2021 2022-2023 •BioCision 2 •GENEWIZ •Abeyance •Barkey •RTS •Matrical •FluidX •PBMMI •RURO •B Medical •Nexus •BioCision 1 •BioStorage •FreezerPro •Trans-Hit Azenta Life •Ziath Technologies •4tit

  22. Slide 22: Portfolio Offering Examples

    Slide 22: Portfolio Offering Examples

    Portfolio Offering Examples Automated Stores Sample Repository Solutions B Medical Systems SampleStoreTM BioStoreTM BioStoreTM III Cryo Consumables & Instruments Genomic Services Sanger Gene Next Sequencing Synthesis Generation Sequencing 22 © 2023 Azenta, Inc. • Proprietary Information

  23. Slide 23: Conference Call Third Quarter Fiscal 2023 Financial Results

    Slide 23: Conference Call Third Quarter Fiscal 2023 Financial Results

    Conference Call Third Quarter Fiscal 2023 Financial Results August 8, 2023

  24. Slide 24: GAAP to Non-GAAP Reconciliation

    Slide 24: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Revenue 139.7 145.5 132.7 137.6 178.4 148.4 165.9 GAAP gross profit 67.0 70.8 59.6 58.1 73.9 53.2 68.0 Gross profit margin 48.0% 48.7% 44.9% 42.3% 41.4%

  25. Slide 25: GAAP to Non-GAAP Reconciliation – Segments

    Slide 25: GAAP to Non-GAAP Reconciliation – Segments

    GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Life Sciences Products Revenue 49.9 53.6 47.4 48.4 89.7 58.9 74.6 GAAP gross profit 22.7 26.3 21.0 19.1 33.0 14.3 27.2 Gross profit margin 45.5% 49.0% 44.4%

  26. Slide 26: Revenue and Gross Margin Quarterly Trend

    Slide 26: Revenue and Gross Margin Quarterly Trend

    Revenue and Gross Margin Quarterly Trend Continuing Operations Non GAAP Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 63.8 Genomics Gross Margin 32.6 32.1 27.3 28.2 28.9 28.2 29.5 Genomics Gross Margin % 51.0% 49.4% 46.0% 45.0% 47.4% 45.4% 46.

  27. Slide 27: GAAP to Non-GAAP Reconciliation – Genomics and SRS

    Slide 27: GAAP to Non-GAAP Reconciliation – Genomics and SRS

    GAAP to Non-GAAP Reconciliation Continuing Operations – Genomics and SRS $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Life Sciences Services- Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 63.8 GAAP gross profit 31.1 31.1 25.9 26.5 27.7 27.0 28.3 Gross profit margin 48.7% 47.9%

  28. Slide 28: GAAP to Non-GAAP Reconciliation – B Medical and Products ex B Medical

    Slide 28: GAAP to Non-GAAP Reconciliation – B Medical and Products ex B Medical

    GAAP to Non-GAAP Reconciliation Continuing Operations – B Medical and Products ex B Medical $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 B Medical Revenue - - - - 41.8 15.1 26.8 GAAP gross profit - - - - 14.1 (1.3) 4.8 Gross profit margin - - - - 33.7% (8.7%) 17.9%

  29. Slide 29: Net Income to Adjusted EBITDA Reconciliation

    Slide 29: Net Income to Adjusted EBITDA Reconciliation

    Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Net income 43.3 2,119.9 (9.6) (20.8) (11.2) (4.9) (1.5) (Income) Loss from discontinued operations, net of tax (40.5) (2,121.7) 2.6 15.5 - 2.9 (1.0) Net income (Loss)

  30. Slide 30: Operating Profit to Adjusted EBITDA Reconciliation

    Slide 30: Operating Profit to Adjusted EBITDA Reconciliation

    Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – Segments Life Science Products Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Operating Profit (Loss) 4.2 5.0 2.0 (0.1) (3.8) (16.4) (4.9) Adjustments: Depreciation 0.7 0.9 0.9 1.2 3.1 3.3 2.9 Amortization of intangi

  31. Slide 31: Operating Profit to Adjusted EBITDA Reconciliation

    Slide 31: Operating Profit to Adjusted EBITDA Reconciliation

    Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – B Medical and Products ex B Medical B Medical Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Operating Profit (Loss) - - - - (0.5) (9.0) (4.1) Adjustments: Depreciation - - - - 2.1 2.0 1.9 Amortization of intangible

  32. Slide 32: Calculation of Organic Revenue Excluding COVID

    Slide 32: Calculation of Organic Revenue Excluding COVID

    Calculation of Organic Revenue Excluding COVID Continuing Operations Growth Metrics $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Revenue 18% 12% 3% 0% 28% 2% 25% Acquisitions/divestitures (2%) (1%) 0% (3%) (33%) (13%) (24%) Currency exchange rates (0%) 1% 3% 4% 4% 3% 0% Organic

Source: company website

More decks from Azenta, Inc.

All 52 Azenta decks